Capillary Technologies Grants 7,92,636 Stock Options Under ESOP Plan 2021
Capillary Technologies India Limited has granted stock options to eligible employees under the ESOP Plan 2021. The grant was approved by the Nomination and Remuneration Committee (NRC) of the Board of Directors on July 3, 2026.The company allocated a total of 7,92,636 stock options, each carrying a face value of ₹ 2/-. This action is part of the ongoing ESOP Plan 2021 for the organization's employees.
According to details provided by the company regarding this grant, the exercise pricing differs based on the recipient's residency status. For recipients who are not US tax residents, the Exercise Price is set at INR 418/- per option, reflecting a 19.84% discount from the Fair Market Value approved by the NRC. Alternatively, employees who are residents of the United States or are subject to US income taxation have an Exercise Price of INR 521.47 per Option.
The terms governing these stock options include vesting over three to four years, provided that other stipulated conditions in their grant letters are met. The duration within which the options may be exercised is set at ten years from the date of vesting or twelve years from the date of Listing, whichever period is later.
Key details regarding the grant of options under the ESOP Plan 2021 are summarized below:
| Particulars | Details |
|---|---|
| Stock Options Granted | 7,92,636 |
| Face Value per Option | ₹ 2/- |
| Exercise Price (Non-US residents) | INR 418/- per Option |
| Exercise Price (US residents) | INR 521.47 per Option |
| Vesting Period | Three to Four Years, subject to grant letter conditions |
| Options Exercisable Within | 10 years from vesting or 12 years from Listing (whichever is later) |
CAPILLARY Stock Price Movement
Capillary Technologies India Limited shares settled on Friday, edging up by 1.94% after closing at ₹515.05. The stock saw a traded volume of 250,618 shares during the session, with prices ranging between a low of ₹505 and a high of ₹519.8.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.